Search Results
Dec 05, 2025, 13:14 ET Clinical Education Alliance Becomes Decera Clinical, Delivering Education, Insights, and Communications
Company brings its Scientific Activation™ mission to life at ASH Annual Meeting following November rebrand RESTON, Va., Dec. 5, 2025 /PRNewswire/ -- Clinical Education Alliance completed its rebrand
More news about: Decera Clinical
Dec 05, 2025, 12:46 ET Sobi to Showcase Scientific advances and Commitment to Haematology at ASH 2025
Dec. 5, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), today announced its participation at the 65th American Society of Hematology (ASH) Annual Meeting, taking place on 6 – 9 December in Orlando, Florida. At this year's meeting, Sobi will showcase its commitment to advancing care in haematology
More news about: Swedish Orphan Biovitrum AB
Dec 05, 2025, 08:00 ET K36 Therapeutics announces presentation of First-in-Human Clinical Data for Gintemetostat (KTX-1001) Demonstrating Target Engagement and Clinical Activity in Multiple Myeloma at ASH 2025 and the Appointment of Dr. Shinta Cheng, M.D., Ph.D., as Chief Medical Officer
cancers, today announced that clinical data from its lead program, gintemetostat (KTX-1001) will be presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6 -9, 2025, in Orlando, Florida. The oral presentation will feature the results from the dose escalation
More news about: K36 Therapeutics
Dec 05, 2025, 08:00 ET Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting
relapsed or refractory (R/R), newly diagnosed and post-transplant maintenance settings, will be presented at the upcoming American Society of Hematology (ASH) Annual Meeting taking place from 6-9 December 2025 in Orlando, Fla.
More news about: Astellas Pharma Inc.
Dec 05, 2025, 08:00 ET Blueprint Medicines, a Sanofi Company, Highlights Long-Term Clinical Benefit of AYVAKIT® (avapritinib) Across Indolent and Advanced Systemic Mastocytosis at 2025 ASH Annual Meeting
to improve SM care, Blueprint Medicines will report one oral presentation and seven poster presentations at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9 in Orlando, Florida.
More news about: Blueprint Medicines, a Sanofi company
Dec 04, 2025, 12:20 ET Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
combination with azacitidine and venetoclax for relapsed or refractory AML have been accepted for presentation at the American Society of Hematology (ASH) Annual Meeting in December 2025."We remain highly encouraged by the continued, strong execution across our programs and the expanding body
More news about: USA News Group
Dec 04, 2025, 08:00 ET MPN Research Foundation Has Two Abstracts Accepted for Presentation at ASH 2025 on Research about Treating and Living with Myeloproliferative Neoplasms
respected and global influential member of the MPN landscape, has two abstracts accepted for the 67th American Society of Hematology (ASH) Annual Meeting and Exposition (ASH 2025). In an oral presentation, the MPN Research Foundation highlights the results of its 2024 global assessment
More news about: MPN Research Foundation
Dec 04, 2025, 07:29 ET Amity University Hosts HR Conclave 2025: Strengthening the critical link between Academia and Industry
was attended by over 400 students from Amity Business School (ABS), Amity Institute of Information Technology (AIIT), and Amity School of Hospitality (ASH), along with faculty and leadership, delivered several salient points, including in-depth understanding of how technology is reshaping talent management
More news about: Amity University Rajasthan
Dec 04, 2025, 03:00 ET iOnctura initiates Phase I/II trial in patients with myelofibrosis ahead of new non-clinical data at ASH
investigations of roginolisib in peripheral T-cell lymphoma and chronic lymphocytic leukemia (CLL) will also be presented at ASH.iOnctura poster presentations at the 67th ASH Annual Meeting in Orlando, Florida, USA:1. A Vannucchi et al. Trial in progress: Sunday, December
More news about: iOnctura
Dec 03, 2025, 12:00 ET ImpriMed to Present Ex Vivo Drug Sensitivity Data in Acute Myeloid Leukemia in Oral Presentation at American Society of Hematology Annual Meeting
selected to present two significant research studies at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida, taking place December 6-10. "Being featured at ASH is an important validation of our xCellSense® platform for both pharma partners and clinicians,"
More news about: ImpriMed
Dec 03, 2025, 10:20 ET OneOncology and OneR Partner Practice Investigators to Present Broad Portfolio of Data at the 2025 American Society of Hematology Annual Meeting
recognize the scientific contributions of its partner practice investigators whose work will be presented at the 2025 American Society of Hematology (ASH) Annual Meeting, December 6–9.
More news about: OneOncology, LLC.
Dec 03, 2025, 10:00 ET Florida Cancer Specialists & Research Institute Contributing To Breakthroughs In Treatment of Blood Cancers & Disorders
2025 ASH Annual Meeting and Exposition can be found here: ASH Annual
More news about: Florida Cancer Specialists & Research Institute
Dec 03, 2025, 08:30 ET Foresight Diagnostics Announces Multiple Presentations in Lymphoma Featuring PhasED-Seq™ Ultrasensitive MRD Analysis at the upcoming ASH Annual Meeting
multiple lymphoma studies featuring Foresight CLARITY™ (PhasED-Seq) minimal residual disease (MRD) analysis at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6–9, 2025, in Orlando, Florida.
More news about: Foresight Diagnostics, Inc.
Dec 02, 2025, 17:25 ET Fuse Appoints Former Director of the Defense Counterintelligence and Security Agency and Palantir Executive to Advisory Board
Defense and Commerce, to include as Deputy Chief of Staff to former Defense Secretary Chuck Hagel and Chief of Staff to the late former Deputy Secretary Ash Carter. She also served as a professional staff member on the Homeland Security and Governmental Affairs Committee and Senate Select Committee on Intelligence.On
More news about: Fuse Energy Technologies Corporation
Dec 02, 2025, 08:15 ET AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
Dec. 2, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will unveil new data at the 2025 American Society of Hematology (ASH) Congress, showcasing continued advances in research across multiple blood cancers including — multiple myeloma (MM), follicular lymphoma (FL), chronic
More news about: AbbVie Inc.
Dec 02, 2025, 08:00 ET Rutgers Cancer Institute and RWJBarnabas Health to Showcase Practice-Changing Blood Cancer Research at the 67th American Society of Hematology Annual Meeting and Exposition
blood cancers, such as lymphoma, leukemia and multiple myeloma, as well as classical hematology disorders at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6–9, 2025, in Orlando, Florida (and online). Rutgers Cancer Institute, New Jersey's only National
More news about: Rutgers Cancer Institute and RWJBarnabas Health
Dec 02, 2025, 07:00 ET Solu Therapeutics Announces Presentation of Trial in Progress on STX-0712 for Treatment of Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia at ASH Annual Meeting
the treatment of chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) in a poster session at the American Society of Hematology (ASH) Annual Meeting being held December 6–9, 2025, in Orlando, Florida.
More news about: Solu Therapeutics
Dec 02, 2025, 06:00 ET CHASM Drives Green Concrete Innovation, Strengthening Norman, Oklahoma's Advanced Materials Leadership
Economic Development Coalition. By enabling greater use of greener, lower-cost supplementary cementitious materials (SCMs) such as fly ash, volcanic ash, calcined clay, slag and limestone, NTeC®-C delivers true sustainability without the green premium—reducing both carbon emissions and
More news about: CHASM Advanced Materials
Dec 01, 2025, 15:16 ET The Patina Collective & Artist Jesse Draxler Debut "The Machine of Loving Grace"
intimacy—balancing precision and empathy, utility and reflection.The project builds on themes central to Draxler's practice, seen in works such as CRASH and C2ASH, which explore fragmentation, personal mythology, and narrative collapse. Rather than engaging in automotive fetishism, C280 situates mechanical forms
More news about: The Patina Collective
Dec 01, 2025, 10:17 ET OncoPrecision Announces Oral Presentation of ONC001, a First-in-Class CD64-Targeting ADC for Monocytic Leukemia, at the 67th ASH Annual Meeting
biology, announced that data from its development candidate, ONC001, has been selected for an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6–9, 2025, in Orlando, Florida.
More news about: OncoPrecision Corporation
Dec 01, 2025, 10:17 ET OncoPrecision Announces Oral Presentation of ONC001, a First-in-Class CD64-Targeting ADC for Monocytic Leukemia, at the 67th ASH Annual Meeting
biology, announced that data from its development candidate, ONC001, has been selected for an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6–9, 2025, in Orlando, Florida.
More news about: OncoPrecision Corporation
Dec 01, 2025, 10:17 ET OncoPrecision gibt an, dass es auf der 67. ASH-Jahrestagung eine mündliche Präsentation zu ONC001, einem erstklassigen CD64-gerichteten ADC für monozytäre Leukämie, durchführen wird
zu seinem Entwicklungskandidaten ONC001 für eine mündliche Präsentation auf der 67. Jahrestagung und Ausstellung der American Society of Hematology (ASH) ausgewählt wurden, die vom 6. bis 9. Dezember 2025 in Orlando, Florida, stattfindet.
More news about: OncoPrecision Corporation
Dec 01, 2025, 10:17 ET OncoPrecision anuncia la presentación oral de ONC001, un ADC dirigido a CD64 para la leucemia monocítica
OncoPrecision anuncia la presentación oral de ONC001, un ADC dirigido a CD64 de primera clase para la leucemia monocítica, en la 67ª Reunión Anual de la ASHNUEVA YORK, 1 de diciembre de 2025 /PRNewswire/ --
More news about: OncoPrecision Corporation
Dec 01, 2025, 10:17 ET Lors de la 67e réunion annuelle de l'ASH, OncoPrecision a annoncé la présentation orale de ONC001, un conjugué anticorps-médicament ciblant le récepteur CD64, premier de sa catégorie, pour la leucémie monocytaire.
candidat au développement, ONC001, ont été sélectionnées pour une présentation orale lors de la 67e réunion annuelle de l'American Society of Hematology (ASH), qui se tiendra du 6 au 9 décembre 2025 à Orlando, en Floride.
More news about: OncoPrecision Corporation
Dec 01, 2025, 08:00 ET Blood Cancer United Showcases Bold Research and Vision at 2025 ASH Annual Meeting
bloodcancerunited.org/research.Additional details on key presentations from Blood Cancer United funded researchers at ASH are available below. The full ASH Annual Meeting 2025 abstracts are available
More news about: Blood Cancer United® formerly The Leukemia & Lymphoma Society